Takara Bio Inc. (TYO:4974)

Market Cap	111.87B
Revenue (ttm)	45.81B
Net Income (ttm)	577.00M
Shares Out	120.42M
EPS (ttm)	4.79
PE Ratio	193.87
Forward PE	42.59
Dividend	17.00 (1.85%)
Ex-Dividend Date	Mar 28, 2025

Volume	242,900
Average Volume	521,285
Open	927.00
Previous Close	919.00
Day's Range	919.00 - 935.00
52-Week Range	711.00 - 1,141.00
Beta	0.33
RSI	57.20
Earnings Date	Nov 11, 2025

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and test...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,779
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4974

Financial Performance

In 2024, Takara Bio's revenue was 45.04 billion, an increase of 3.53% compared to the previous year's 43.51 billion. Earnings were 1.04 billion, a decrease of -29.66%.